


BTK en B cel receptor signalering in systemische autoimmuun ziekten


Odilia Corneth
Afdeling Longziekten
Erasmus MC Rotterdam

3 februari 2023

Bruton's tyrosine kinase




Bruton's tyrosine kinase in B cellen





Hendriks et al, Nat Rev Cancer 2014

BTK is essentieel voor normale B cel ontwikkeling en activatie




XLA: geen functioneel BTK eiwit




Nomura et al, Blood 2000


BTK is betrokken bij meerdere signalerings routes in B cellen



BTK eiwit wordt opgereguleerd na stimulatie




In vitro stimulatie (3d)



Kil et al., Blood, 2012


BTK in autoimmuniteit



Genetische analyses (GWAS):

- Het *BTK* locus is **geen** risico locus
- Maar: veel genen in de drie belangrijkste signalerings pathways waarin BTK een rol speelt zijn wel risico loci






Btk overexpressie in B cellen



Btk wordt opgereguleerd na BCR stimulatie:

Zijn BTK eiwit levels cruciaal voor normale B cel functie?



Spontaan autoimmun fenotype in BTK transgene muizen



Kil et al., Blood, 2012

B-T cel interactie is essentieel voor het autoimmuun fenotype


Geen B cel activatie zonder B-T cel interactie



Corneth et al., *J Immunol*, 2016


Model B-T cel interactie in autoimmuniteit

- Verhoogd BTK leidt tot:
 - verhoogde activatie van B cellen
 - spontane GCs en plasma cellen
 - spontaan autoimmuun fenotype
- B-T cel interactie is essentieel voor het fenotype





BTK inhibitie bij autoimmuniteit in muizen


Collageen-geïnduceerde artritis



MRL-Fas(lpr) lupus muizen



BTK inhibitie in monocyten




CGI-1746 verlaagt cytokine productie in Ig complex-geactiveerde humane monocyten

Di Paolo et al., Nat Chem Biol 2011


Relevantie voor de mens




≠




Verhoogde BTK eiwit expressie in ACPA+ reumatoïde arthritis patiënten



Verhoogd BTK in B cellen in ACPA+ RA





Correlatie BTK eiwit met pathogene T cellen



Corneth et.al., *Arthritis Rheumatol*, 2016



Verstoorde BCR signalering in ACPA+ RA patiënten




Neys et.al., unpublished

Verhoogd BTK eiwit in Sjögren patiënten is afhankelijk van B-T cel interactie

Verhoogd BTK eiwit in Sjögren





Abatacept behandeling verlaagt BTK eiwit







Corneth et.al., *Arthritis Rheumatol*, 2016

BTK inhibitie is heel effectief in CLL



Herman et al, 2014

'Rewiring' van BCR signalering na BTK inhibitie *in vivo*



BTK inhibitie in MS


The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE


Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

Xavier Montalban, M.D., Ph.D., Douglas L. Arnold, M.D., Martin S. Weber, M.D.,
 Ivan Staikov, M.D., Ph.D., Karolina Piasecka-Stryczynska, M.D., Ph.D.,
 Jonathan Willmer, M.D., Emily C. Martin, Ph.D., Fernando Dangond, M.D.,
 Sana Syed, M.D., M.P.H., and Jerry S. Wolinsky, M.D.,
 for the Evobrutinib Phase 2 Study Group*

A Total No. of Lesions at Wk 12 through 24



Lesion rate ratio (95% CI)	1.45 (0.72–2.91)	0.30 (0.14–0.63)	0.44 (0.21–0.93)
Adjusted P value vs. placebo	0.32	0.005	0.06
Unadjusted P value vs. placebo	0.29	0.002	0.03



Pulmonary Medicine

Jasper Rip
Stefan Neys
Marjolein de Bruijn
Rudi Hendriks

Rheumatology

Sandra Paulissen
Jan Piet van Hamburg
Nadine Davelaar
Erik Lubberts

Target 2 B



Cynthia Fehres
Jeska de Vries-Bouwstra
Rene Toes



Gwenny Verstappen
Frans Kroese



Rene Ysermans
Matthias Busch
Elizabeth Raveling
Pieter van Paassen

Anouk von Borstel
Wayel Abdulahad
Peter Heeringa
Bram Rutgers